Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699450 | 0.85 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL12165436 | 0.85 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL13352355 | 0.83 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL10613798 | 0.83 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| Hydrochloric Acid SCHEMBL3925422 | 0.83 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL4560773 | 0.83 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL12165437 | 0.82 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL12165442 | 0.82 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL12281621 | 0.81 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL17215122 | 0.80 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3OPRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080177110-A1 | Processes for the synthesis of O-desmethylvenlafaxine | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-07-24 | — | — | US | claimed |
| EP-1917237-A2 | PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE | Teva Pharmaceutical Industries Ltd (IL) | 2008-05-07 | — | — | EP | claimed |
| WO-2008013994-A2 | PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-31 | — | — | WO | claimed |
| US-20080177110-A1 | Processes for the synthesis of O-desmethylvenlafaxine | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-07-24 | — | — | US | disclosed |
| US-20080177110-A1 | Processes for the synthesis of O-desmethylvenlafaxine | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-07-24 | — | — | US | disclosed |
| US-20080177110-A1 | Processes for the synthesis of O-desmethylvenlafaxine | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-07-24 | — | — | US | disclosed |
| EP-1917237-A2 | PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE | Teva Pharmaceutical Industries Ltd (IL) | 2008-05-07 | — | — | EP | disclosed |
| JP-2008088159-A | PROCESS FOR SYNTHESIS OF O-DESMETHYLVENLAFAXINE | TEVA PHARMACEUTICAL INDUSTRIES LTD | 2008-04-17 | — | — | JP | disclosed |
| WO-2008013994-A2 | PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177110-A1 | Processes for the synthesis of O-desmethylvenlafaxine | CYP4F3, CYP3A4, CYP2D6 | SLC6A2 53/4885SLC6A4 37/4885SLC6A3 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.